Holocene Advisors LP Has $470.23 Million Stake in Astrazeneca Plc $AZN

Holocene Advisors LP increased its position in shares of Astrazeneca Plc (NYSE:AZN) by 41.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,129,194 shares of the company’s stock after acquiring an additional 1,807,565 shares during the quarter. Astrazeneca comprises about 1.1% of Holocene Advisors LP’s investment portfolio, making the stock its 9th largest position. Holocene Advisors LP’s holdings in Astrazeneca were worth $470,232,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AZN. Binnacle Investments Inc raised its holdings in Astrazeneca by 21.8% during the 3rd quarter. Binnacle Investments Inc now owns 660 shares of the company’s stock worth $51,000 after purchasing an additional 118 shares during the last quarter. Chapin Davis Inc. boosted its stake in shares of Astrazeneca by 3.3% in the 3rd quarter. Chapin Davis Inc. now owns 3,795 shares of the company’s stock valued at $291,000 after purchasing an additional 120 shares during the last quarter. 44 Wealth Management LLC boosted its stake in shares of Astrazeneca by 0.7% in the 3rd quarter. 44 Wealth Management LLC now owns 16,722 shares of the company’s stock valued at $1,283,000 after purchasing an additional 124 shares during the last quarter. CoreCap Advisors LLC grew its position in shares of Astrazeneca by 30.6% during the 3rd quarter. CoreCap Advisors LLC now owns 534 shares of the company’s stock worth $41,000 after buying an additional 125 shares during the period. Finally, Highline Wealth Partners LLC raised its stake in shares of Astrazeneca by 32.0% during the third quarter. Highline Wealth Partners LLC now owns 532 shares of the company’s stock worth $41,000 after buying an additional 129 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Astrazeneca Stock Performance

Shares of NYSE AZN opened at $190.20 on Monday. Astrazeneca Plc has a 52-week low of $122.48 and a 52-week high of $212.71. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 0.51. The company has a market cap of $294.98 billion, a P/E ratio of 32.77, a PEG ratio of 1.43 and a beta of 0.32.

Astrazeneca Dividend Announcement

The company also recently declared a dividend, which will be paid on Monday, March 23rd. Stockholders of record on Friday, February 20th will be issued a $1.595 dividend. The ex-dividend date of this dividend is Friday, February 20th. This represents a dividend yield of 156.0%. Astrazeneca’s payout ratio is 66.26%.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on AZN. Barclays restated an “overweight” rating on shares of Astrazeneca in a report on Tuesday, January 6th. Wall Street Zen downgraded Astrazeneca from a “buy” rating to a “hold” rating in a research note on Thursday. HSBC restated a “buy” rating and issued a $108.00 price target on shares of Astrazeneca in a research report on Wednesday, December 10th. Citigroup initiated coverage on Astrazeneca in a report on Tuesday, January 27th. They issued a “buy” rating for the company. Finally, TD Cowen reissued a “buy” rating on shares of Astrazeneca in a research note on Tuesday, December 9th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $95.75.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.